Revlimid (lenalidomide): Ongoing Safety Review – Increased Risk of Developing New Malignancies

Audience: Hematology, Oncology ISSUE: FDA is informing the public that we are aware of results from clinical trials conducted inside and outside the United States that found that patients treated with Revlimid (lenalidomide) may be at an increased…

Related posts:

1. Abacavir – Ongoing Safety Review: Possible Increased Risk of Heart Attack Audience: Infectious Disease including Ziagen, Trizivir, and Epzicom ISSUE: FDA...